No confirmation of publications for confirmatory studies
| Generic name | Company | Drug indications where conditions fulfilled | Number of required confirmatory studies* | Date drug received Notice of Compliance with conditions (year-month-day) | Date drug fulfilled conditions (year-month-day) |
| Amprenavir | GlaxoSmithKline | HIV/AIDS—two indications | Unknown (all relevant material removed) | 2001-03-01 2001-11-21 | 2004-07-05 2004-07-05 |
| Anastrozole | AstraZeneca | Breast cancer | 1 (company responded but did not confirm publication) | 2004-06-20 | 2008-12-02 |
| Aztreonam | Gilead Science | Cystic fibrosis | 1 | 2009-07-17 | 2011-05-17 |
| Dabrafenib | Novartis | Multiple myeloma | 3 | 2015-03-06 | 2016-05-13 |
| Deferasirox | Novartis | Transfusion-related iron overload | 12 | 2016-02-14 | 2017-01-10 |
| Deferasirox | Novartis | Thalassaemia | 1 | 2006-10-18 | 2016-12-02 |
| Delavirdine | Viiv Healthcare Canada | HIV/AIDS—two indications | 6 | 1998-07-22 2000-04-25 | 2003-07-22 2003-07-22 |
| Imatinib | Novartis | Gastrointestinal stromal tumour; chronic myeloid leukaemia—two indications | 9 | 2001-09-20 2003-10-08 2007-04-24 | 2004-12-29 2010-06-17 2013-02-21 |
| Letrozole | Novartis | Breast cancer; Breast cancer | 3 | 2005-04-01 2006-10-06 | 2010-12-17 2010-12-17 |
| Nevirapine | Boehinger Ingelheim | HIV/AIDS | Unknown (all relevant material removed) | 1998-09-04 | 2004-09-13 |
| Nilotinib | Novartis | Chronic myeloid leukaemia—three indications | 3 | 2008-09-09 2010-07-22 2011-06-23 | 2011-11-30 2011-08-18 2015-08-19 |
| Raltegravir | Merck Frosst | HIV/AIDS | 2 | 2007-11-27 | 2009-03-04 |
| Riluzole | Aventis | Amyotrophic lateral sclerosis | 1 (Company letter said results of study disclosed in Product Monograph but letter and Product Monograph did not give any information about whether or not study was published) | 2000-08-30 | 2007-11-29 |
| Tenofovir | Gilead Science | HIV/AIDS | 3 | 2003-03-18 | 2005-07-20 |
| Trametinib | Novartis | Melanoma | 3 | 2016-03-11 | 2016-05-13 |
↵*Based on information in Qualifying Notices (see text for definition of Qualifying Notice).